Study on the symptom control of gastric acid suppressive drugs in reflux esophagitis patients
- Conditions
- Reflux esophagitis
- Registration Number
- JPRN-UMIN000029032
- Lead Sponsor
- Marru-clinic Yokosuka Department of Gastroenterology
- Brief Summary
In the results, between the PCAB (5 cases/30 cases, 33%) and PPI (6 cases/30 cases, 40.0%) groups in the proportion of patients with a positive symptom score of at least 1 point at 2 weeks after discontinuation, there was no statistically significant difference (chi-square test, p = 0.705) . Negative symptom scores were not also statistically significantly different between the PCAB (7 cases, 46%) and PPI (4 cases, 26.7%) groups (chi-square test, p = 0.256).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Not provided
1. Patients with warning signs such as vomiting, gastrointestinal bleeding (including findings of hematemesis, melena, and anemia), and sudden weight loss 2. Patients confirmed or suspected malignant lesion 3. Patients with a history of gastrointestinal resection or vagotomy 4. Patients in Irritable Bowel Syndrome 5. Patients whose participation in this study would be contraindicated due to complications such as serious hepatic disease, renal disease, or cardiac disease 6. Women who are pregnant or who may possibly be pregnant, and lactating mothers 7. Other patients whom the investigator considers unsuitable for admission to the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Gerd Q total score of heartburn and acid regurgitation
- Secondary Outcome Measures
Name Time Method 1. Gerd Q each score of heartburn and acid regurgitation Degrees of heartburn and acid regurgitation 2. Gerd Q each score of epigastralgia, nausea and vomiting Degrees of epigastralgia, nausea and vomiting 3. Evaluation of treatment response with Gerd Q